Xilio Therapeutics (XLO) Amortization of Deferred Charges (2020 - 2024)
Xilio Therapeutics (XLO) reported Amortization of Deferred Charges of -$1000.0 for Q1 2024, down 103.23% on a YoY basis from $31000.0 in Q2 2023, and down 106.25% sequentially from $16000.0 in Q4 2023.
Xilio Therapeutics (XLO) Amortization of Deferred Charges (2020 - 2024) Analysis & Trends
Xilio Therapeutics (XLO) has 5 years of Amortization of Deferred Charges data on file, last reported at -$1000.0 in Q1 2024.
- For the quarter ending Q1 2024, Amortization of Deferred Charges fell 103.23% year-over-year to -$1000.0; the trailing twelve-month figure through Sep 2024 stood at $15000.0 (down 92.5% YoY), and the FY2023 full-year result was $157000.0, down 29.6% from the prior year.
- Amortization of Deferred Charges slipped to -$1000.0 in Q1 2024, from $16000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $87000.0 in Q2 2023 to a low of -$1000.0 in Q1 2024.
- A 5-year average of $42357.1 and a median of $42000.0 in 2020 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges jumped 64.15% in 2023 and tumbled 103.23% in 2024, its largest moves.
- Tracing XLO's Amortization of Deferred Charges over 5 years: stood at $41000.0 in 2020, then grew by 26.83% to $52000.0 in 2021, then advanced by 13.46% to $59000.0 in 2022, then plunged by 72.88% to $16000.0 in 2023, then tumbled by 106.25% to -$1000.0 in 2024.
- Business Quant data shows XLO's Amortization of Deferred Charges at -$1000.0 in Q1 2024, $16000.0 in Q4 2023, and $23000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Sep 30, 2023 | 23,000.00 |
| Sep 30, 2023 | 23,000.00 |
| Jun 30, 2023 | 87,000.00 |
| Jun 30, 2023 | 87,000.00 |
| Mar 31, 2023 | 31,000.00 |
| Mar 31, 2023 | 31,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 58,000.00 |
| Sep 30, 2022 | 58,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Dec 31, 2021 | 52,000.00 |
| Dec 31, 2021 | 52,000.00 |